Arrowhead Pharmaceuticals, Inc. (ARWR) News
Follow Arrowhead Pharmaceuticals, Inc. (ARWR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 47 public stories across 23 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Arrowhead Wins UK Marketing Authorisation for REDEMPLO
The MHRA approved REDEMPLO (plozasiran) for adults with familial chylomicronaemia syndrome who have not responded adequately to diet and conventional triglyceride-lowering therapies. The treatment is also available on th
REGULATION | Oct 27, 2026, 10:03 PM UTC
M
MHRA Grants Marketing Authorisation for Arrowhead’s REDEMPLO
Arrowhead Pharmaceuticals says the UK Medicines and Healthcare products Regulatory Agency granted marketing authorisation for REDEMPLO for adults with familial chylomicronaemia syndrome (FCS).
REGULATION | Oct 27, 2026, 04:42 PM UTC
M
UK NICE Recommends NHS Funding for Arrowhead’s Redemplo in Adults With FCS
The UK National Institute for Health and Care Excellence recommends NHS funding for Redemplo (plozasiran) for adults with genetically confirmed familial chylomicronemia syndrome.
REGULATION | Oct 27, 2026, 03:37 PM UTC
M
MHRA Grants Marketing Authorisation for Redemplo in Adults With FCS
Arrowhead Pharmaceuticals says the MHRA granted marketing authorisation for Redemplo (plozasiran) to treat familial chylomicronemia syndrome in adults.
REGULATION | Oct 27, 2026, 03:37 PM UTC
M
Arrowhead’s Redemplo Wins UK Approval to Treat FCS
Arrowhead said its plozasiran treatment, marketed as Redemplo, received approval in the United Kingdom for familial chylomicronemia syndrome (FCS).
REGULATION | Oct 27, 2026, 03:37 PM UTC
M
Arrowhead’s Redemplo Wins UK Approval
Arrowhead Pharmaceuticals’ Redemplo received UK approval for a rare cholesterol disorder.
REGULATION | Oct 27, 2026, 03:37 PM UTC
M
UK MHRA Authorizes Arrowhead’s REDEMPLO for FCS
REDEMPLO (plozasiran) received MHRA marketing authorization as an adjunct to diet to reduce triglycerides. NICE also backed NHS funding in England and Wales.
REGULATION | Oct 27, 2026, 03:36 PM UTC
L
Arrowhead reports interim Phase 1/2a ARO-MAPT data
The company says clinical data in healthy volunteers demonstrated deep and durable tau reductions.
EQUITY | Oct 14, 2026, 11:34 AM UTC
L
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead’s central ne
NEWS | Sep 29, 2026, 11:30 AM UTC
L
Arrowhead Pharmaceuticals Price Target Announced at $74.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 12:02 PM UTC
L
ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near
Arrowhead Pharmaceuticals (ARWR) is drawing fresh Wall Street attention after Goldman Sachs resumed coverage of the biotechnology company with a ‘Neutral’ rating and $74 price target. The firm highlighted its preference
EQUITY | Sep 24, 2026, 11:21 AM UTC
H
Nasdaq 100 Slips, 10-Year Yields Hit 19-Year Highs: Stock Market Today
U.S. stocks slid at midday Wednesday as the 10-year Treasury yield surged to its highest level since 2007, after blowout September PMI data cemented bets for another Federal Reserve rate hike and sent traders scrambling
LIVE | Sep 23, 2026, 05:08 PM UTC
L
These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right. — Barrons.com
By Mackenzie TatananniFrom speculation over mergers and acquisitions to the hype surrounding clinical readouts, it seems biotechnology stocks are all the rage this year.The iShares Biotechnology exchange-traded fund has
NEWS | Sep 23, 2026, 05:45 AM UTC
M
ARWR falls after first human results for ARO-DIMER-PA
Arrowhead Pharmaceuticals shares fell over 10% on Tuesday after posting first human results for experimental ARO-DIMER-PA, a shot intended to silence two cholesterol genes with one molecule.
EQUITY | Sep 15, 2026, 07:04 PM UTC
H
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The U.S. 10-year Treasury yield broke above 5% on Tuesday, and crude oil stormed past $105 a barrel, a combination that left every major U.S. equity index in the red at midday. President Donald Trump said on Truth Social
LIVE | Sep 15, 2026, 05:27 PM UTC
L
ARWR: First-in-class dual gene knockdown, strong triglyceride reduction, and expanding innovative pipeline
ARO-DIMER-PA achieved first-in-class dual gene knockdown with strong early efficacy and safety, while plozasiran's launch in FCS exceeded expectations and demonstrated robust triglyceride reduction and safety. The pipeli
NEWS | Sep 15, 2026, 04:50 PM UTC
L
ARWR: Dual gene knockdown, strong clinical data, and AI-driven innovation highlight broad pipeline progress
Breakthrough dual gene knockdown was achieved with ARO-DIMER-PA, showing strong efficacy in mixed hyperlipidemia and a clear path to pivotal trials. The plozasiran launch is progressing well, with robust clinical data an
NEWS | Sep 15, 2026, 04:35 PM UTC
L
ARWR - Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
ARWR - Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
NEWS | Sep 15, 2026, 11:40 AM UTC
L
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being de
NEWS | Sep 15, 2026, 11:30 AM UTC
H
Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus
Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets.On Friday, the Do
NEWS | Sep 13, 2026, 01:11 PM UTC
L
Citigroup starts Arrowhead Pharmaceuticals with a $108 price target
Citigroup initiated coverage on Arrowhead Pharmaceuticals with a buy rating and announced a $108.00/share price target.
EQUITY | Sep 08, 2026, 04:14 PM UTC
L
Arrowhead Pharmaceuticals to participate in September 2026 investor conferences
Arrowhead Pharmaceuticals will participate in upcoming September 2026 investor conferences.
EQUITY | Sep 03, 2026, 11:32 AM UTC
L
Arrowhead Pharmaceuticals scheduled for September 2026 investor conferences
Arrowhead Pharmaceuticals (ARWR) announced it will participate in the 2026 Cantor Global Healthcare Conference (September 9-11, 2026), including a fireside chat on September 10 at 10:55 am EDT.
EQUITY | Sep 03, 2026, 11:30 AM UTC
H
Investors Shrug Off Good News for Heart Patients From New Meds — Barrons.com
By Bill AlpertThis year's run in drug stocks gained vigor from new treatments for heart attacks and strokes. Maybe some of those stocks are losing wind.At this past weekend's congress of the European Society of Cardiolog
GEOPOLITICS | Sep 01, 2026, 07:27 PM UTC
L
HC Wainwright keeps Arrowhead Pharmaceuticals price target at $120.00
HC Wainwright & Co. maintained a $120.00/share price target for Arrowhead Pharmaceuticals, according to ratings actions reported by Benzinga via TradingView News.
EQUITY | Sep 01, 2026, 10:31 AM UTC
L
ARWR: Plozasiran delivers paradigm-shifting efficacy and safety for SHTG, targeting high-risk patients first
ARWR: Plozasiran delivers paradigm-shifting efficacy and safety for SHTG, targeting high-risk patients first
EQUITY | Aug 31, 2026, 02:28 PM UTC
M
ARWR says ploza(s)iran robust in Phase 3 sHTG trial
ARWR says ploza(s)iran showed robust efficacy and safety in Phase 3 sHTG trials, supporting global regulatory filings.
EQUITY | Aug 31, 2026, 07:50 AM UTC
L
ARWR - Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in P
ARWR - Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
EQUITY | Aug 30, 2026, 03:40 PM UTC
M
Arrowhead presents Phase 3 SHASTA-3/4 data for plozasiran in severe hypertriglyceridemia
Arrowhead Pharmaceuticals presented Phase 3 SHASTA-3 and SHASTA-4 data on plozasiran for patients with severe hypertriglyceridemia.
EQUITY | Aug 30, 2026, 03:30 PM UTC
L
Arrowhead Pharmaceuticals to present new clinical data at ESC Congress
Arrowhead Pharmaceuticals says it will present new clinical data at the European Society of Cardiology Congress.
GEOPOLITICS | Aug 24, 2026, 11:36 AM UTC
L
ARWR: Germany patients get access to REDEMPLO (plozasiran)
ARWR says people living with familial chylomicronaemia syndrome (FCS) in Germany have access to REDEMPLO (plozasiran) as a new treatment option to reduce triglycerides.
REGULATION | Aug 17, 2026, 01:34 PM UTC
L
ARWR - Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
ARWR - Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
EARNINGS | Aug 04, 2026, 08:13 PM UTC
L
ARWR - Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
ARWR - Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
REGULATION | Aug 04, 2026, 08:02 PM UTC
L
ARWR - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
ARWR - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
EQUITY | Aug 03, 2026, 08:35 PM UTC
L
ARWR Arrowhead Pharmaceuticals completes enrollment in global phase 3 yosemite study of zodasiran for the treatment of homozygous familial h
ARWR Arrowhead Pharmaceuticals completes enrollment in global phase 3 yosemite study of zodasiran for the treatment of homozygous familial hypercholesterolemia Arrowhead Pharmaceuticals - yosemite phase 3 study completio
EQUITY | Jul 27, 2026, 11:30 AM UTC
L
IONS Competitor ARWR data meets the Bar in SHTG @ GSCO
IONS Competitor ARWR data meets the Bar in SHTG @ GSCO
EQUITY | Jul 23, 2026, 12:21 PM UTC
H
Stock Market Today: Nasdaq 100 Falls as Crude Rallies to $88
U.S. stocks traded in split fashion by midday Wednesday, with a resilient Dow and S&P 500 masking softer breadth as rising oil prices and fresh tariffs kept a lid on risk appetite ahead of the first “Magnificent Seven” e
CENTRAL_BANK | Jul 22, 2026, 04:58 PM UTC
H
Crude Oil Gains 2%; GE Vernova Shares Fall After Q2 Earnings
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 200 points on Wednesday. The Dow traded up 0.40% to 52,432.64 while the NASDAQ declined 0.01% to 25,834.80. The S&P 500
MACRO | Jul 22, 2026, 04:09 PM UTC
H
CME Group, Weatherford International, RPM International And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining around 200 points on Wednesday. Shares of CME Group Inc (NASDAQ: CME ) rose sharply following upbeat quarterly earnings. CME posted second-quarter adjusted EPS of
EARNINGS | Jul 22, 2026, 02:04 PM UTC
L
ARWR shares +17% premarket after said phase 3 SHASTA-3 and SHASTA-4 studies of Plozasiran in severe Hypertriglyceridemia met primary endpoin
ARWR shares +17% premarket after said phase 3 SHASTA-3 and SHASTA-4 studies of Plozasiran in severe Hypertriglyceridemia met primary endpoints. In SHASTA-3 and SHASTA-4, 25 mg Plozasiran administered as a subcutaneous in
EQUITY | Jul 22, 2026, 12:54 PM UTC
L
ARWR Arrowhead Pharmaceuticals - plozasiran achieves 79% and 81% median triglyceride reduction in shasta-3 and shasta-4 - Plozasiran shows s
ARWR Arrowhead Pharmaceuticals - plozasiran achieves 79% and 81% median triglyceride reduction in shasta-3 and shasta-4 - Plozasiran shows significant reduction in acute pancreatitis events, 100% in high-risk patients -
REGULATION | Jul 22, 2026, 11:30 AM UTC
L
ARWR Arrowhead Pharmaceuticals reports topline results from phase 3 shasta-3 and shasta-4 studies of plozasiran in patients with severe hype
ARWR Arrowhead Pharmaceuticals reports topline results from phase 3 shasta-3 and shasta-4 studies of plozasiran in patients with severe hypertriglyceridemia
EQUITY | Jul 22, 2026, 11:30 AM UTC
L
ARWR new Buy W/ $98 PT @ Stifel
ARWR new Buy W/ $98 PT @ Stifel
EQUITY | Jul 14, 2026, 11:05 AM UTC
L
ARWR Initiate with a Buy, $98 PT @ Stifel
ARWR Initiate with a Buy, $98 PT @ Stifel
EQUITY | Jul 13, 2026, 08:08 PM UTC
L
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $100 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ: ARWR ) with a Buy and maintains $100 price target.
EQUITY | Jul 01, 2026, 03:57 PM UTC
H
ARWR: Receives EU Approval
Arrowhead Pharmaceuticals receives European Commission marketing authorization for REDEMPLO to lower triglyceride levels in adult patients with familial chylomicronemia syndrome
EQUITY | Jun 22, 2026, 05:23 PM UTC
H
ARWR Receives EU Approval
Arrowhead Pharmaceuticals receives EU marketing authorization for REDEMPLO to reduce triglycerides in adults with Familial Chylomicronemia Syndrome
EQUITY | Jun 22, 2026, 04:33 PM UTC